TD Cowen analyst Gary Taylor lowered the firm’s price target on P3 Health Partners (PIII) to $3 from $6 and keeps a Hold rating on the shares. The firm updated its model following Q3 results and said its target reflects reflects 0.2x its 2027 revenue estimates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PIII:
- Maintaining Hold Amid Weak Near-Term Results but Potential Profitability by 2027 for P3
- Morning Movers: AstraZeneca jumps following tozorakimab trial results
- P3 Health Partners price target lowered to $4 from $12.50 at Lake Street
- Closing Bell Movers: Argan jumps 10% on earnings beat
- P3 Health Partners reports Q4 revenue $384.8M, two estimates $357.7M